Levoketoconazole
Cushing’s syndrome treatment maintains reductions in urinary free cortisol for 12 months
Most adults with Cushing’s syndrome receiving levoketoconazole twice daily maintained reductions in mean urinary free cortisol levels during a 12-month maintenance period, according to findings from the SONICS study extended evaluation.
LOGICS: Levoketoconazole improves cortisol control in endogenous Cushing’s syndrome
SAN DIEGO — Compared with placebo, levoketoconazole improved cortisol control and serum cholesterol levels for adults with endogenous Cushing’s syndrome, according to results from the LOGICS study presented here.
FDA approves levoketoconazole for Cushing’s syndrome
The FDA approved the steroidogenesis inhibitor levoketoconazole for adults with Cushing’s syndrome for whom surgery is not an option or has not been curative, according to an industry press release.
FDA accepts NDA for novel Cushing’s syndrome treatment
The FDA accepted for review a new drug application for the steroidogenesis inhibitor levoketoconazole for the treatment of endogenous Cushing’s syndrome, according to an industry press release.